Nektar Therapeutics went quiet on September 8, 2026, and will stay that way until it releases the 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. That timing is the only public signal the company has given about when the data arrive.
The follow-up read matters because it tests durability, not just response. The on-treatment results from REZOLVE-AA were already positive in the 92-patient study, but alopecia areata tends to relapse once treatment stops, and that is the question baricitinib and ritlecitinib have had to answer in post-approval practice. If rezpegaldesleukin, a regulatory T-cell agonist targeting the IL-2 receptor complex, shows durable hair regrowth after dosing ends, it would offer a mechanistically distinct answer to that durability problem rather than another JAK inhibitor competing on the same pharmacology as the two currently FDA-approved options.
The enrolled population adds an important wrinkle: all 92 patients were JAK-inhibitor-naive and biologic-naive. That design choice protects the signal from prior-treatment confounding, but it also means the durability read applies specifically to treatment-naive patients, not to the larger pool of people who have already cycled through baricitinib or ritlecitinib. Whether Nektar pursues a label that addresses that refractory population will depend on what Phase 3 looks like, and the off-treatment data will do a lot to shape that design decision.
Nektar notes the quiet period follows the same pattern it used for earlier REZOLVE study disclosures, so there is no structural surprise in the filing itself. The question is purely what the data show. Once the follow-up readout lands, the off-treatment durability curve will be the number that determines whether this mechanism earns a Phase 3 design that can compete in a field already defended by oral daily therapies with multi-year safety records.
Source link: https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/ea0304798-8k_nektar.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
